Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

BACKGROUND: Treatment of acute myeloid leukemia (AML) remains difficult due to the development of treatment resistance which might be overcome through antagonists of inhibitors of apoptosis proteins (IAPs). PATIENTS AND METHODS: This multi-center, open-label, dose escalation study aimed to evaluate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Lymphoma Myeloma Leuk
Hauptverfasser: DiPersio, John F., Erba, Harry P., Larson, Richard A., Luger, Selina M., Tallman, Martin S., Brill, Jeffrey M., Vuagniaux, Gregoire, Rouits, Elisabeth, Sorensen, J. Mel, Zanna, Claudio
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5028895/
https://ncbi.nlm.nih.gov/pubmed/25842225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.02.020
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge